379270-37-8

• 常用中文名：替诺福韦艾拉酚胺
• 常用英文名：Tenofovir alafenamide
• CAS号：379270-37-8
• 分子式：C₂₁H₂₉N₆O₅P
• 分子量：476.466
• 相关类别： 原料药 抑制剂
• 发布时间：2018-02-06 08:00:00
• 更新时间：2026-07-01 16:46:59
• GS-7340(Tenofovir alafenamide)是抗病毒药物替诺福韦（Tenofovir）的前体药物，相比TFV disoproxil fumarate，GS-7340能更好的将TFV送达淋巴细胞和组织。

名称

• 中文名: 替诺福韦艾拉酚胺
• 英文名: propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
• 中文别名: 磷丙替诺福韦(别名:GS7340); 替诺福韦艾拉酚胺(TAF BASE); 富马酸丙酚替诺福韦对照品; 替诺福韦拉酚氨酯杂质21(替诺福韦艾拉酚胺杂质)对照品(FREE BASE); (S)-2-(((S)-((((R)-1-(6-氨基-9H-嘌呤-9-基)丙-2-基)氧基)甲基)(苯氧基)磷酰基)氨基)丙酸异丙酯; 富马酸替诺福韦甲酰胺; 替诺福韦杂质51; 替诺福韦和阿拉芬胺; 替诺福韦艾拉酚胺,10 MM DMSO 溶液; 替诺福韦-阿拉芬酰胺-D6; 泰诺福韦富马酸酯; 替诺福韦艾拉酚胺杂质; 替诺福韦阿拉芬酰胺; 泰诺福韦艾拉酚胺杂质; N-[(S)-[[(1R)-2-(6-氨基-9H-嘌呤-9-基)-1-甲基乙氧基]甲基]膦酸酯基]-L-丙氨酸 1-甲基乙基酯; 富马酸替诺福韦艾拉酚胺TAF; 替诺福韦艾拉酚胺半富马酸盐; 泰诺福韦艾拉酚胺; 替诺福韦-丙芬酰胺; 替诺福韦艾拉酚胺(TFA); 替诺福韦阿拉芬胺; (S)-丙胺酸异丙酯2-{(S)-[((R)-1-(6-氨基-9H-嘌呤-9-基)-1-甲基乙氧基]甲基}-苯氧基磷酰基; 氘6-替诺福韦阿拉芬胺(外消旋体混合物); 磷丙替诺福韦; 泰诺福韦艾拉酚胺(GS-7340); 富马酸替诺福韦艾拉酚胺; 丙酚替诺福韦; 泰诺福韦艾拉酚胺游离碱; 磷丙替诺福韦(富马酸替诺福韦艾拉酚胺); 替诺福韦艾拉酚胺中间体2; 替诺福韦艾拉酚胺原料药及其全线产品以及工艺; 替诺福韦艾拉酚胺 Tenofovir alafenamide; 替诺福韦丙氨苯丙酰胺; L-丙氨酸,N-[(S)-[[(1R)-2-(6-氨基-9H-嘌呤-9基)-1-甲基乙氧基]甲基]苯氧基氧膦基],1-甲基乙基酯; 替诺福韦艾拉酚胺(GS-7340); 替诺福韦艾拉酚胺富马酸盐 1392-7
• 英文别名: Tenofovir Alafenamide N-2; Alafenamide; Isopropyl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate; Tenofovir Alafenamide (GS-7340); L- Alanine,N-[(S)-[[(1R)-2-(6; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl); Tenofovir Alafenamide Impurity; GS-7340/GS7340; GS-7340; L-Alanine, N-[(S)-[(1S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester; Tenofovir alafenamide, 10 mM in DMSO; Tenofovir Alafenamide（TAF）(Fumate)（GS-7340）; Tenofovir Alafenamide(TAF)(GS-7340); TENOFOVIR ALAFENAMIDE; GS7340; GS; Tenofovir alafenamide fumage; Tenofovir Alafenamide free base; GS7340; (2S)-isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; isopropyl ((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate; tenofovir alafenamide; propan-2-yl (2S)-2-{[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propa n-2-yl]oxy}methyl)(phenoxy)phosphoryl]amino}pr opanoate; Tenofovir Alafenamide (100mg/mL in Methanol); Tenofovir alafenamide semifumate; Tenofovir Alafenamide //BP; Tenofovir alafenamide Intermediate 2; Tenofovir Impurity 51; N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy)phosphoryl]-L-alanine isopropyl ester; Tenofovir Alafenamide 25 mg tablets; Tenofovir Alafenamide fumate, N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy)phosphoryl]-L-alanine isopropyl ester; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; GS-7340-03; GS-7340 Tenofovir alafenamide; Sp-Tenofovir-phosphonamidate,phenyl,L-alanine isopropyl ester; Tenofovir Alafenamide Base; N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-L-alanine 1-methylethyl ester; N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy); Tenofovir and alafenamide; GS7340; GS-7340; GS 7340; TAF; TENOFOVIR ALAFENAMIDE; GENVOYA; Tenofovir Alafenamide-d6; D6-Tenofovir Alafenamide(Mixture of Diastereomers); L-Alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester; N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy] methyl]phenoxyphosphinyl]-L-alanine 1-methylethyl; phenyl hydrogen ((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate; (2R,3S)-2,3-bis(4-chlorophenyl)butane-2,3-diamine

物化性质

• 密度: 1.39±0.1 g/cm3
• 沸点: 640.4±65.0 °C at 760 mmHg
• 分子式: C₂₁H₂₉N₆O₅P
• 分子量: 476.466
• 闪点: 341.1±34.3 °C
• 精确质量: 476.193695
• PSA: 153.29000
• LogP: 2.20
• 外观性状: 白色粉末
• 蒸汽压: 0.0±1.9 mmHg at 25°C
• 折射率: 1.630
• 储存条件: 室温，干燥
• 水溶解性: Practically insoluble (0.04 g/L) (25 ºC)

生物活性

• 描述: Tenofovir alafenamide (GS-7340) 是 Tenofovir 的前体,Tenofovir 是一种 HIV-1 核苷酸逆转录酶抑制剂。
• 相关类别:
  信号通路 >> 抗感染 >> HIV
  信号通路 >> 抗感染 >> 逆转录酶
  研究领域 >> 感染
• 靶点:

  HIV-1, NRTIs[1]

• 体外研究: 所有细胞类型的替诺福韦艾拉酚胺抗病毒活性相似,范围为5至7 nM,而MT-4和MT-2细胞的CC50分别为4.7至42μM。针对一组HIV-1和HIV-2分离株评估TAF的抗病毒活性,包括HIV-1组M亚型A至G,以及N和O组分离株。总体而言,对于在PBMC中测试的29种初级HIV-1分离株,TAF EC50的范围为0.1至12nM,平均EC50为3.5nM,而AZT的平均EC50为11.8nM,其用作内部对照。对于HIV-2分离株,TAF的平均EC50为1.8 nM,AZT的平均EC50为6.4 nM [2]。
• 体内研究: Tenofovir alafenamide hemifumarate是替诺福韦的酰胺类前药,与替诺福韦地索普西富马酸盐(TDF)相比具有良好的口服生物利用度并增加血浆稳定性[1]。
• 参考文献:

  [1]. Babusis D, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66.

  [2]. Ruane PJ, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55.

安全

• 危害码 (欧洲): Xi

合成路线

39825-33-7 379270-35-6 ~% 379270-37-8 383365-04-6

文献：Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628

147127-20-6 ~% 379270-37-8

文献：Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628

39613-92-8 ~% 379270-37-8

文献：Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ;

379270-35-6 ~% 379270-37-8

文献：Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ;

101-02-0 ~% 379270-37-8

文献：Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ;

108-95-2 ~% 379270-37-8

文献：Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628

上下游产品

上游产品  6
39825-33-7 379270-35-6 147127-20-6 39613-92-8
101-02-0 108-95-2
下游产品  0